Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor

NCT02533765 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Neoplasms, Germ Cell and Embryonal

Interventions

DRUG: Olaparib

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS